CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-18 | Ogden Christopher SVP, Finance and Accounting | Grant or award · Stock Option (Right to Buy) | +154,000 | 154,000 | ||
| 2024-01-18 | Ogden Christopher SVP, Finance and Accounting | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2024-01-18 | Landau Jeffrey B Chief Business Officer | Grant or award | +30,000 | 116,622 | ||
| 2024-01-18 | Landau Jeffrey B Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2024-01-18 | Landau Jeffrey B Chief Business Officer | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2024-01-18 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +26,250 | 181,374 | ||
| 2024-01-18 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +122,500 | 122,500 | ||
| 2024-01-18 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2024-01-18 | Chu Yu-Waye Chief Medical Officer | Grant or award | +26,250 | 26,250 | ||
| 2024-01-18 | Chu Yu-Waye Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +122,500 | 122,500 | ||
| 2024-01-18 | Chu Yu-Waye Chief Medical Officer | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2023-12-20 | McCarthy Sean A. CEO | Sale | −13,551 | $1.38 | $19K | 454,704 |
| 2023-12-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −4,077 | $1.38 | $6K | 155,124 |
| 2023-12-20 | Landau Jeffrey B Chief Business Officer | Sale | −4,077 | $1.38 | $6K | 86,622 |
| 2023-12-20 | ROWLAND LLOYD A General Counsel | Sale | −4,077 | $1.38 | $6K | 97,996 |
| 2023-12-20 | Ogden Christopher SVP, Finance and Accounting | Sale | −1,990 | $1.38 | $3K | 48,657 |
| 2023-12-17 | Ogden Christopher SVP, Finance and Accounting | Option exercise | +6,875 | 50,647 | ||
| 2023-12-17 | Ogden Christopher SVP, Finance and Accounting | Option exercise · Performance Stock Units (PSUs) | −6,875 | 6,875 | ||
| 2023-12-17 | McCarthy Sean A. CEO | Option exercise | +37,500 | 468,255 | ||
| 2023-12-17 | McCarthy Sean A. CEO | Option exercise · Performance Stock Units (PSUs) | −37,500 | 37,500 |
Page 7 of 33 · 649 trades